Mónica Paulina Manzano Vela

Mónica Paulina Manzano Vela

Auto-generated profile, based on publicly available information

Mónica Paulina Manzano Vela

Universidad de las Fuerzas Armadas- ESPE, Departamento de Ciencias Médicas. Sangolquí, Ecuador

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2024 in Revista Científica de Salud y Desarrollo Humano
Verified
Journal Article
Open access
PDF file
MVMónica Paulina Manzano Vela
Mónica Paulina Manzano Vela
Objetivo: Esta revisión sistemática tiene como objetivo analizar la prevalencia, tendencias epidemiológicas y estrategias de prevención de la hepatitis A en niños menores de 6 años. Metodología: Se realizó una búsqueda bibliográfica en bases de datos científicas (Pubmed, Scielo, Redalyc, Medigraphic, Springer, Taylor & Francis, Elsevier) y reportes oficiales de la OMS, considerando publicaciones en inglés y español entre los años 2019 y 2024. Se aplicaron criterios de inclusión y exclusión para seleccionar estudios relevantes sobre la epidemiología y prevención de la hepatitis A en la población pediátrica. Resultados: Se incluyeron 14 estudios en la revisión tras un proceso de selección por relevancia y calidad. Los datos analizados muestran una disminución en la incidencia de hepatitis A en países con programas de vacunación implementados. La vacunación no solo reduce la prevalencia, sino también la gravedad de los casos. Mejores condiciones sanitarias y prácticas higiénicas, junto con la vacunación, han contribuido a la reducción de la tasa de incidencia y al aumento de la edad promedio de infección. Se destaca la importancia de la vacunación en la población pediátrica, especialmente en áreas de alta endemicidad, y la necesidad de estudios a largo plazo para evaluar la duración de la inmunidad y la posible necesidad de dosis de refuerzo. Conclusiones: La vacunación contra la hepatitis A ha demostrado ser una estrategia efectiva para reducir la carga de la enfermedad en niños. Es fundamental mejorar las condiciones sanitarias, aumentar la cobertura vacunal en población pediátrica desfavorecida, y promover la vacunación en grupos de alto riesgo. Se requieren más estudios para optimizar las estrategias de prevención y avanzar hacia la meta de eliminación de la hepatitis A.

3 September 2024 in Salud, Ciencia y Tecnología
Verified
Journal Article
Open access
PDF file
GOGalo Fernando Tulcanaza Ochoa
Galo Fernando Tulcanaza Ochoa
PCPaulina Elizabeth Cisneros Clavijo
Paulina Elizabeth Cisneros Clavijo
JTJavier Lizandro Meza Tonato
Javier Lizandro Meza Tonato
PGPaola Gissela Placencia Guartatanga
Paola Gissela Placencia Guartatanga
MVMónica Paulina Manzano Vela
Mónica Paulina Manzano Vela
NPNéstor Raúl Parrales Ponce
Néstor Raúl Parrales Ponce
Introduction: Atrial fibrillation (AF) is a prevalent arrhythmia with significant health and economic impacts. Traditional detection methods like 12-lead ECGs and Holter monitors are effective but limited by cost and patient compliance. Wearable devices, such as smartwatches and patches, offer a promising alternative for real-time AF detection.Objective: This systematic review aims to evaluate the efficacy of wearable cardiac monitoring devices compared to traditional methods in detecting AF.Methods: A comprehensive literature search identified studies comparing wearable devices to traditional methods for AF detection. Data on sensitivity, specificity, and usability were extracted and analyzed. A pooled analysis using both fixed-effect and random-effects models assessed overall sensitivity and specificity.Results: This systematic review analyzed data from 15 studies comparing wearable devices to traditional methods for AF detection. Wearable devices, including smartwatches, patch-type ECGs, and PPG-based technologies, showed high sensitivity and specificity, with the fixed-effect model estimating overall sensitivity at 91.59% and specificity at 92.13%. The random-effects model provided slightly higher sensitivity (94.03%) and specificity (95.96%). Smartwatches like the Apple Watch with KardiaBand demonstrated up to 97.5% sensitivity, comparable to insertable cardiac monitors (ICMs). Patch-type ECGs, such as MobiCARE-MC100 and Zio XT, matched Holter monitors in accuracy, with extended monitoring enhancing AF detection. PPG-based technologies, exemplified by the WATCH AF trial, showed 93.7% sensitivity and 98.2% specificity. Despite high accuracy, significant heterogeneity among studies highlighted the need for standardized protocols.Conclusion: Wearable devices show high sensitivity and specificity for AF detection, comparable to traditional methods. However, substantial heterogeneity indicates the need for standardized protocols and further research to optimize these technologies for clinical use.

1 January 2025 in Salud, Ciencia y Tecnología
Verified
Journal Article
Open access
PDF file
MVMónica Paulina Manzano Vela
Mónica Paulina Manzano Vela
DVDennis Renato Manzano Vela
Dennis Renato Manzano Vela
AFAna Carola Flores
Ana Carola Flores
MCMarco Vinicio Parra Chávez
Marco Vinicio Parra Chávez
Introduction: Down Syndrome (DS) is a genetic disorder caused by trisomy of chromosome 21, resulting in intellectual disability and an increased risk of congenital malformations. Advances in genetic and molecular diagnostics have improved the accuracy and speed of DS diagnosis, including next-generation sequencing (NGS) and whole exome sequencing (WES).Methods: A systematic narrative review was applied to analyze the most recent genetic and molecular tools applied to DS diagnosis as well as the clinical conceptualization of the disease. The review included sources from the last five years, extracted from databases such as PubMed, Scopus, and Web of Science. After critical analysis, 40 articles were selected from an initial total of 72 primary sources.Results: NGS and WES technologies have shown diagnostic sensitivity greater than 99% for DS, with false-positive rates below 0.5%. In prenatal diagnosis, non-invasive prenatal diagnosis (NIPD) using cell-free fetal DNA (cffDNA) in maternal plasma has achieved detection rates above 98%, reducing the need for invasive methods such as amniocentesis. Postnatally, molecular techniques such as real-time PCR (qPCR) and comparative genomic hybridization arrays (CGH-array) have reduced diagnostic times to less than 72 hours.Conclusions: Genetic and molecular tools, especially NGS, WES, and NIPD, have revolutionized the diagnosis of DS, offering greater precision and speed while minimizing risks. Future research should focus on validating these methods for widespread use, especially in low-risk populations, and exploring the potential of WES to detect comorbidities associated with DS.